Research & KnowledgeEvent: September 3, 2026
nference published a peer-reviewed study in Biology Methods and Protocols highlighting routine care signals from sustained initiation-dose GLP-1 therapy in a federated real-world dataset of de-identified U.S. patients.
Published
Signal category
Research & Knowledge
Quote
“Thank you, Ken Alltucker and USA TODAY for highlighting the questions emerging from our recent nference study on routine care signals”
— Venky Soundararajan, Ph.D.|nference team
Company
nference
Making biomedical knowledge computable
- Industry
- Biotechnology Research
- Location
- Cambridge, US
- Company size
- 313 employees
nference leverages the top academic minds, world-class researchers, and real-time access to multimodal, patient-level data to accelerate drug development innovation, generate evidence, and improve clinical trial processes. nSights, our flagship software platform, delivers the most comprehensive biological and clinical insights into patient care.
Founded 2013